Craft

Tandem Diabetes Care

Stock Price

$32.9

2024-10-29

Market Capitalization

$2.2 B

2024-10-29

Revenue

$1 B

FY, 2025

Tandem Diabetes Care Summary

Company Summary

Overview
Tandem Diabetes Care is a medical device company that engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. It offers insulin pumps such as t:slim X2 and Tandem Mobi, both equipped with Control-IQ technology for automated insulin delivery based on data from integrated continuous glucose monitoring (CGM) sensors. The company also supplies single-use components such as insulin cartridges and infusion sets. Tandem Diabetes Care provides t:connect, a data management application to display diabetes therapy management data, integrated CGMs, and supported blood glucose meters.
Type
Public
Status
Active
Founded
2006
HQ
San Diego, CA, US | view all locations
Website
https://www.tandemdiabetes.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • John Sheridan

    John Sheridan, President and Chief Executive Officer, Director

  • Leigh Vosseller

    Leigh Vosseller, Executive Vice President, Chief Financial Officer and Treasurer

  • Elizabeth Gasser

    Elizabeth Gasser, Executive Vice President and Chief Strategy and Product Officer

  • Jordan Pinsker

    Jordan Pinsker, Chief Medical Officer

    Operating MetricsView all

    Facilities Leased (US), square feet

    417K
    13.6%

    FY, 2022

    Pumps Shipped to Date

    420K
    27.3%

    FY, 2022

    Products

    3

    FY, 2022

    LocationsView all

    3 locations detected

    • San Diego, CA HQ

      United States

      12400 High Bluff Drive

    • Markham, ON

      Canada

      675 Cochrane Dr Tower – 6th Floor

    • Schiphol, NH

      Netherlands

      Schiphol Boulevard 359

    Tandem Diabetes Care Financials

    Summary Financials

    Revenue (Q1, 2026)
    $247.2M
    Gross profit (Q1, 2026)
    $136.8M
    Net income (Q1, 2026)
    ($20.4M)
    Cash (Q1, 2026)
    $179.3M
    EBIT (Q1, 2026)
    ($17.4M)
    Enterprise value
    $2.7B

    Footer menu